Companies / BOC Sciences / Briakinumab
BOC Sciences

Briakinumab | BOC Sciences

Briakinumab is a human anti-IL-12 monoclonal antibody developed for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and Crohn's Disease.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.